美国 BioTrove 
基因组分析用仪器和耗材生产与营销商BioTrove Inc.向证交会申请首次公开发行价值7500万美元的股票，由Piper Jaffray和Lazard Capital Markets担任承销商。这家总部位于马萨诸塞州Woburn的公司计划将其股票以“BTRV”为交易代码在纳斯达克上市。该公司2007财年亏损1900万美元，营收470万美元，2006财年亏损1250万美元，营收270万美元
2009-11-10，公司宣布收购基因组学技术公司

BioTrove, Inc. advances life science and drug discovery research through two revolutionary micro- and nano-scale technologies. A privately held Company, BioTrove is backed by leading venture capitalist firms Catalyst Health and Technology Partners, CB Health Ventures, Vox Equity Partners I & II, Echelon Ventures and Fletcher Spaght, Inc.

BioTrove's innovative platform technologies dramatically increase throughput for pharmaceutical screening and genomics research, accelerating drug-discovery decisions and pipeline development.

OpenArray™ technology enables researchers to perform more than 3,000 assays simultaneously, generating single nucleotide polymorphism (SNP) or Real Time quantitative polymerase chain reaction (qPCR) data in the hundreds of thousands of data points per day. Large-scale studies require the examination of hundreds of loci for hundreds or thousands of nucleic acid samples.
RapidFire™ Mass Spectrometry (RF-MS) uses an innovative microfluidic technology to facilitate sample analysis at faster than 10 seconds per sample - 10 to 100 times faster than conventional technologies. The speed of RapidFire™ technology makes MS-based screening economically viable by overcoming the throughput bottleneck.